Justin Winas, DO
Pain Medicine · Fort Washington, PANPI 1679789010
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 346 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,306 and has fallen 61.9% since, to $879 in 2025.
Across 346 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Abbott$860
- Collegium Pharmaceutical, Inc.$854
- Nevro Corp.$722
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$613
- Vertos Medical, Inc.$529
- plus $3K from 32 others
Across 1 payment — averaging $700.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$700
What the payments were for
- Travel & lodging$3394%
- Food & beverage$7,42096%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$204
- Senza Spinal Cord Stimulation System$148
- mild Device Kit$138
- Omnia$132
- PENTA$127
How this compares
$7,759 in reported general payments places this provider in the 85th percentile of 294 pain medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 19 | $89,121 |
| OxycontinOxycodone Hcl | 88 | $70,438 |
| Nucynta ErTapentadol Hcl | 42 | $69,376 |
| Xtampza ErOxycodone Myristate | 68 | $40,155 |
| Buprenorphine | 98 | $24,756 |
| Nurtec OdtRimegepant Sulfate | 13 | $24,372 |
| Oxycodone Hcl | 839 | $21,542 |
| Fentanyl | 83 | $15,874 |
| Chlorzoxazone | 12 | $11,344 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 478 | $10,993 |
| BelbucaBuprenorphine Hcl | 13 | $10,783 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 372 | $9,925 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 62 | $9,159 |
| Emgality PenGalcanezumab-Gnlm | 12 | $7,812 |
| Morphine Sulfate ErMorphine Sulfate | 230 | $6,613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er, Belbuca | $854 | $120,313123 claims |
| PfizerNurtec Odt | $147 | $24,37213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 294 pain medicine providers in Pennsylvania.
Other pain medicine in Fort Washington
- Peter PryzbylkowskiPhiladelphia$506K
- Yeshvant NavalgundGreensburg$388K
- Jack SmithWilliamsport$324K
- Sanjay GuptaBala Cynwyd$241K
- Vwaire OrhurhuWilliamsport$191K
- Philip KimBryn Mawr$128K
- Ajay WasanPittsburgh$66K
- Sanjay ShahSpring House$64K
- Soon JungAllentown$58K
- Bruce NicholsonAllentown$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.